Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Has Consensus Target Price of $355.38 According to Brokerages

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) has earned an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $355.38.

Several research analysts have recently weighed in on LGND shares. Barclays increased their price objective on shares of Ligand Pharmaceuticals from $345.00 to $350.00 and gave the stock an “overweight” rating in a report on Wednesday, November 11th. Leerink Partners initiated coverage on shares of Ligand Pharmaceuticals in a report on Friday, August 14th. They issued an “outperform” rating and a $330.00 target price for the company. Citigroup upped their price target on shares of Ligand Pharmaceuticals from $397.00 to $402.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. Weiss Ratings downgraded shares of Ligand Pharmaceuticals from a “buy (b)” rating to a “hold (c)” rating in a research note on Monday, November 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $358.00 price target on shares of Ligand Pharmaceuticals in a research note on Thursday, September 24th.

Check Out Our Latest Stock Analysis on LGND

Insider Activity at Ligand Pharmaceuticals

In other news, Director Martine Zimmermann sold 2,000 shares of the company’s stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $318.17, for a total transaction of $636,340.00. Following the completion of the sale, the director directly owned 1,782 shares in the company, valued at $566,978.94. This represents a 52.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Jason Aryeh sold 3,000 shares of the company’s stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $320.05, for a total value of $960,150.00. Following the sale, the director owned 105,476 shares of the company’s stock, valued at approximately $33,757,593.80. The trade was a 2.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 24,093 shares of company stock valued at $7,384,287 over the last quarter. 5.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Ligand Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in LGND. Integrated Wealth Concepts LLC acquired a new stake in Ligand Pharmaceuticals during the second quarter worth about $27,000. Jacobi Capital Management LLC acquired a new position in shares of Ligand Pharmaceuticals in the 3rd quarter valued at about $31,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Ligand Pharmaceuticals in the 2nd quarter valued at about $75,000. MCF Advisors LLC lifted its stake in shares of Ligand Pharmaceuticals by 118.9% in the 2nd quarter. MCF Advisors LLC now owns 243 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 132 shares in the last quarter. Finally, Covestor Ltd lifted its stake in shares of Ligand Pharmaceuticals by 49.8% in the 3rd quarter. Covestor Ltd now owns 337 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 112 shares in the last quarter. Hedge funds and other institutional investors own 91.28% of the company’s stock.

Ligand Pharmaceuticals Stock Down 2.3%

Shares of NASDAQ:LGND opened at $301.71 on Tuesday. The stock’s 50-day moving average price is $302.03 and its two-hundred day moving average price is $258.58. The company has a current ratio of 1.22, a quick ratio of 1.19 and a debt-to-equity ratio of 0.71. Ligand Pharmaceuticals has a 12-month low of $175.89 and a 12-month high of $326.63. The firm has a market cap of $6.03 billion, a price-to-earnings ratio of 134.69, a PEG ratio of 5.52 and a beta of 1.16.

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The biotechnology company reported $2.67 EPS for the quarter, beating the consensus estimate of $2.33 by $0.34. Ligand Pharmaceuticals had a return on equity of 5.22% and a net margin of 20.27%. The company had revenue of $78.75 million during the quarter, compared to analysts’ expectations of $77.00 million. During the same quarter in the previous year, the business earned $3.09 EPS. The firm’s revenue was down 31.8% on a year-over-year basis. On average, research analysts forecast that Ligand Pharmaceuticals will post 2.35 EPS for the current year.

Ligand Pharmaceuticals Company Profile

(Get Free Report)

Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.

Further Reading

Analyst Recommendations for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.